Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 6/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18107549 | 0.88 | CYP3A4 (0.45) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL180952 | 0.80 | TSHR (0.45) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL9859153 | 0.78 | CYP3A4 (0.44) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| Boric Acid SCHEMBL27919823 | 0.78 | CYP3A4 (0.37) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL11533414 | 0.77 | CYP3A4 (0.42) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL11325205 | 0.77 | CYP3A4 (0.42) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL161063 | 0.77 | CYP3A4 (0.50) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL27334114 | 0.77 | ALDH1A1 (0.41) | CYP3A4TSHRTDP1MAPK1ACACB | |
| SCHEMBL11320855 | 0.77 | CYP3A4 (0.36) | CYP3A4TSHRTRPA1TDP1MAPK1 | |
| SCHEMBL50333 | 0.76 | CYP3A4 (0.54) | CYP3A4TSHRTRPA1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| EP-0241559-B1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4983751-A | Chemical intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4818272-A | NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0241559-A1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | CYP3A4 2358/4885TSHR 1134/4885TRPA1 427/4885 |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | CYP3A4 2358/4885TSHR 1134/4885TRPA1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.